Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice

Stroke

Volumn 46, Issue 1, 2015, Pages 212-220

  Na, Shin Young ^a   Mracsko, Eva ^a   Liesz, Arthur ^a,b,c   Hünig, Thomas ^d   Veltkamp, Roland ^a,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Germany 3 Munich Cluster for Systems Neurology   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

brain ischemia; regulatory T cells

Indexed keywords

INTERLEUKIN 10; MONOCLONAL ANTIBODY CD28; TRANSCRIPTION FACTOR FOXP3; CD28 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BRAIN; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL COUNT; CELL EXPANSION; CELL MIGRATION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEUKOCYTE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE ACTIVATION; VOLUMETRY; AGONISTS; ANIMAL; C57BL MOUSE; CEREBRAL ARTERY DISEASE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; STROKE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MICE, INBRED C57BL; STROKE; T-LYMPHOCYTES, REGULATORY;

EID: 84920167551     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007756     Document Type: Article

References (35)

1. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
2. Liesz A, Zhou W, Mracsko E, Karcher S, Bauer H, Schwarting S, et al. Inhibition of lymphocyte traffcking shields the brain against deleterious neuroinfammation after stroke. Brain. 2011;134:704-720.
3. Wang Q, Tang XN, Yenari MA. The infammatory response in stroke. J Neuroimmunol. 2007;184:53-68.
4. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammad-eltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946-950.
5. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
6. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Göbel K, Schuhmann MK, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood. 2013;121:679-691.
7. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15:192-199.
8. Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. CD4+FoxP3+ regulatory T-cells in cerebral ischemic stroke. Metab Brain Dis. 2011;26:87-90.
9. Stubbe T, Ebner F, Richter D, Engel O, Klehmet J, Royl G, et al. Regulatory t cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. J Cereb Blood Flow Metab. 2013;33:37-47.
10. Li P, Gan Y, Sun BL, Zhang F, Lu B, Gao Y, et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol. 2013;74:458-471.
11. Liesz A, Zhou W, Na SY, Hämmerling GJ, Garbi N, Karcher S, et al. Boosting regulatory T cells limits neuroinfammation in permanent cortical stroke. J Neurosci. 2013;33:17350-17362.
12. Xie L, Sun F, Wang J, Mao X, Xie L, Yang SH, et al. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinfamma-tion and secondary injury via regulatory T cells after focal ischemia. J Immunol. 2014;192:6009-6019.
13. Gogishvili T, Langenhorst D, Lühder F, Elias F, Elfein K, Dennehy KM, et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One. 2009;4:e4643.
14. Lin CH, Hünig T. Effcient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol. 2003;33:626-638.
15. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med. 2005;202:445-455.
16. Schmidt J, Elfein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV, et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specifc monoclonal antibodies. J Neuroimmunol. 2003;140:143-152.
17. Beaudette-Zlatanova BC, Whalen B, Zipris D, Yagita H, Rozing J, Groen H, et al. Costimulation and autoimmune diabetes in bb rats. Am J Transplant. 2006;6:894-902.
18. Beyersdorf N, Ding X, Hünig T, Kerkau T. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. Blood. 2009;114:4575-4582.
19. Guilliams M, Bosschaerts T, Hérin M, Hünig T, Loi P, Flamand V, et al. Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis. 2008;198:781-791.
20. Drummond GB, Paterson DJ, McGrath JC. ARRIVE: new guidelines for reporting animal research. Exp Physiol. 2010;95:841.
21. Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, et al. A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods. 2002;117:207-214.
22. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Res. 1986;379:104-111.
23. Langenhorst D, Gogishvili T, Ribechini E, Kneitz S, McPherson K, Lutz MB, et al. Sequential induction of effector function, tissue migration and cell death during polyclonal activation of mouse regulatory T-cells. PLoS One. 2012;7:e50080.
24. Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, et al. Developmental stage, phenotype, and migration distinguish naive-and effector/memory-like CD4+ regulatory T cells. J Exp Med. 2004;199:303-313.
25. Huehn J, Hamann A. Homing to suppress: address codes for Treg migration. Trends Immunol. 2005;26:632-636.
26. Liesz A, Hagmann S, Zschoche C, Adamek J, Zhou W, Sun L, et al. The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke. 2009;40:2849-2858.
27. Campanella M, Sciorati C, Tarozzo G, Beltramo M. Flow cyto-metric analysis of infammatory cells in ischemic rat brain. Stroke. 2002;33:586-592.
28. Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, et al. Postischemic brain infltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. Brain Pathol. 2013;23:34-44.
29. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299-1307.
30. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.
31. Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161:512-526.
32. Römer PS, Berr S, Avota E, Na SY, Battaglia M, ten Berge I, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 2011;118:6772-6782.
33. Hünig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol. 2012;12:317-318.
34. Tabares P, Berr S, Römer PS, Chuvpilo S, Matskevich AA, Tyrsin D, et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol. 2014;44:1225-1236.
35. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11:119-130.